Approximately 1.5 billion people worldwide are overweight or affected by obesity, and are at
risk of developing type 2 diabetes, cardiovascular disease and related metabolic and …

Laparoscopic Roux-en-Y gastric bypass (LRYGBP) reduces appetite and induces significant
and sustainable weight loss. Circulating gut hormones changes engendered by LRYGBP …

… Patients aged 18 or over, with a BMI ≥40.0 kg/m 2 , or ≥35.0 kg/m 2 in the presence of
at least one obesity-related comorbidity, who underwent either RYGBP or SG as a primary …

Importance Metabolic surgery leads to weight loss and improved health, but these outcomes
are highly variable. Poor weight loss is associated with lower circulating levels of glucagon-…

Aims The comparative efficacy of Roux‐en‐Y gastric bypass (RYGB) and sleeve gastrectomy
on Type 2 diabetes remission and the role of weight loss are unclear. The DiaRem …

Reduced energy intake drives weight loss following Roux-en-Y gastric bypass (RYGB) and
sleeve gastrectomy (SG) procedures. Post-operative changes in subjective appetite, taste, …

… Men listed for bariatric surgery who had a BMI higher than 35 kg/m 2 with obesity-related
comorbidity or a BMI higher than 40 kg/m 2 , 2 age older than 30 years (47.2 ± 8.1), and could …

DNA methylation variations are prevalent in human obesity but evidence of a causative role
in disease pathogenesis is limited. Here, we combine epigenome-wide association and …

… Obesity, defined as a body mass index (BMI) ≥30 kg/m 2 , is an increasingly common health
problem in developed countries. Several digestive disorders, such as gastrooesophageal …

… Mohamed Elkalaawy reports other from Johnson & Johnson, personal fees from WL Gore,
personal fees and other from Olympus Keymed, outside the submitted work. …